OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch

Key Takeaways Ocugen targets multiple 2026-2027 catalysts across OCU400, OCU410ST and OCU410 programs.OCU400 phase III data due Q1 2027, with rolling BLA filing planned in Q3 2026.OCU410 and OCU410ST data readouts and filings could reshape expectations amid high execution risk.Ocugen (OCGN) is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and regulatory steps clustered into 2026 and early 2027. The setup makes the next several quarters especially event ...